ONCODESIGN: Drug candidate’s selection triggers a EUR2m milestone payment from Servier | CORPORATE | EUR15(+18%)
ONCODESIGN - CORPORATE | EUR15(+18%)Drug candidate’s selection triggers a EUR2m milestone payment from Servier
LRRK2 programme in Parkinson’s disease targets IND in 2022
Not first-in-class but aims to become best-in-class
R&D day to be held on June 24
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.